Insulin Glargine News and Research

RSS
Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Insulin degludec has reduced risk of recurrent hypoglycemia than insulin glargine

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Eli Lilly reports positive results from Phase III AWARD trials of type 2 diabetes drug, dulaglutide

Insulin degludec shows promise in diabetes

Insulin degludec shows promise in diabetes

Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

Boehringer Ingelheim, Lilly announce data from LY2605541 Phase II study on type 2 diabetes

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

GW to evaluate effectiveness of glucose-lowering drugs against type 2 diabetes

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Biodel initiates BIOD-123 Phase 2 trial in Type 1 diabetes

Insulin glargine retards progression of atherosclerosis in high-risk people

Insulin glargine retards progression of atherosclerosis in high-risk people

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Degludec reduces risk of nighttime low blood sugar in elderly diabetic adults

Degludec reduces risk of nighttime low blood sugar in elderly diabetic adults

Insulin more effective add-on than sitagliptin in glucose control

Insulin more effective add-on than sitagliptin in glucose control

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Sanofi’s insulin glargine delays progression from pre-diabetes to T2DM

Long-term insulin use does not increase risk of heart disease in people with diabetes

Long-term insulin use does not increase risk of heart disease in people with diabetes

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Sanofi’s Lantus more effective than sitagliptin for people with type 2 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Amylin, Alkermes announce results from BYDUREON clinical study on type 2 diabetes

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

Lilly, Boehringer Ingelheim announce results from linagliptin Phase III trial on T2D

European Commission grants marketing authorization for use of BYETTA with basal insulin

European Commission grants marketing authorization for use of BYETTA with basal insulin

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

BYETTA-basal insulin combination therapy receives EMA CHMP positive opinion

Amylin outlines key strategic priorities for 2012

Amylin outlines key strategic priorities for 2012